Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimebutine maleate + rabeprazole in refractory reflux esophagitis
NCT02986685Phase 4Withdrawn
- Sponsor
- Xijing Hospital of Digestive Diseases
- Start
- Nov 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of trimebutine in gastroesophageal reflux disease (GERD), sponsored by Xijing Hospital of Digestive Diseases. Primary endpoint: Change of main symptom score from baseline to the end of 8 weeks. Planned start Nov 2016; status: withdrawn.
02
Drugs
trimebutine
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT02986685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02986685.